Clinical Trial to Assess Onset of Action of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray Delivered in a Single Spray (Dymista) in the Treatment of Allergen-Induced Allergic Rhinitis Symptoms in Comparison to Placebo in an Environmental Exposure Unit (EEU)
Latest Information Update: 27 Mar 2023
At a glance
- Drugs Azelastine/fluticasone-propionate (Primary)
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors Meda Pharma GmbH & Co KG
- 11 Feb 2022 Status changed from recruiting to completed.
- 10 Sep 2021 Planned End Date changed from 31 Jul 2021 to 31 Jan 2022.
- 10 Sep 2021 Planned primary completion date changed from 31 Jul 2021 to 31 Jan 2022.